Citigroup
IMVT icon

Citigroup’s Immunovant IMVT Stock Holding History

Citigroup’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.66M Sell
49,254
-66,891
-58% -$2.64M ﹤0.01% 2959
2026
Q2 		$4.48M Buy
116,145
+90,795
+358% +$2.77M ﹤0.01% 2245
2026
Q1 		$630K Buy
25,350
+2,465
+11% +$63.8K ﹤0.01% 3406
2025
Q4 		$582K Sell
22,885
-219,137
-91% -$4.89M ﹤0.01% 3498
2025
Q3 		$3.9M Sell
242,022
-75,860
-24% -$1.23M ﹤0.01% 2156
2025
Q2 		$5.09M Buy
317,882
+28,553
+10% +$432K ﹤0.01% 1872
2025
Q1 		$4.94M Buy
289,329
+147,011
+103% +$3.08M ﹤0.01% 1903
2024
Q4 		$3.53M Buy
142,318
+48,980
+52% +$1.39M ﹤0.01% 2304
2024
Q3 		$2.66M Buy
93,338
+61,743
+195% +$1.82M ﹤0.01% 2413
2024
Q2 		$834K Sell
31,595
-218,196
-87% -$6.21M ﹤0.01% 3038
2024
Q1 		$8.07M Buy
249,791
+125,449
+101% +$4.58M 0.01% 1375
2023
Q4 		$5.24M Sell
124,342
-1,974
-2% -$72.6K ﹤0.01% 1561
2023
Q3 		$4.85M Buy
126,316
+38,179
+43% +$863K ﹤0.01% 1449
2023
Q2 		$1.67M Sell
88,137
-197,230
-69% -$3.68M ﹤0.01% 2382
2023
Q1 		$4.43M Buy
285,367
+182,796
+178% +$3.17M ﹤0.01% 1563
2022
Q4 		$1.82M Buy
102,571
+99,612
+3,366% +$1.25M ﹤0.01% 2117
2022
Q3 		$17K Sell
2,959
-2,716
-48% -$13.3K ﹤0.01% 4801
2022
Q2 		$22K Buy
5,675
+353
+7% +$1.52K ﹤0.01% 4940
2022
Q1 		$29K Sell
5,322
-149,177
-97% -$929K ﹤0.01% 4964
2021
Q4 		$1.32M Sell
154,499
-120,550
-44% -$995K ﹤0.01% 2975
2021
Q3 		$2.39M Sell
275,049
-44,829
-14% -$404K ﹤0.01% 2393
2021
Q2 		$3.38M Buy
319,878
+77,257
+32% +$1.08M ﹤0.01% 2250
2021
Q1 		$3.89M Buy
242,621
+224,559
+1,243% +$5.92M ﹤0.01% 1975
2020
Q4 		$834K Buy
18,062
+15,867
+723% +$734K ﹤0.01% 3721
2020
Q3 		$77K Sell
2,195
-10,885
-83% -$327K ﹤0.01% 5299
2020
Q2 		$318K Buy
13,080
+11,452
+703% +$245K ﹤0.01% 4648
2020
Q1 		$25K Buy
+1,628
New +$24.5K ﹤0.01% 6538

Other funds holding IMVT

Two Seas Capital
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
Banque Pictet & Cie
Banque Pictet & Cie Geneva 73, Switzerland $14.5B AUM 33.71% 1-Year Est. Return
STRS Ohio
STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $184B AUM 51.71% 1-Year Est. Return
China Universal Asset Management Company
China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Citigroup's IMVT Position: Q3 2026 in Review

Citigroup reduced its Immunovant (IMVT) stake by 58% in Q3 2026, selling an estimated $2.64M and leaving 49,254 shares worth $1.66M. The position accounts for ﹤0.01% of the portfolio, ranked #2959.

Citigroup first reported a position in IMVT in Q1 2020 and has held it in 27 quarters since. The position peaked at $8.07M in Q1 2024. 50 funds tracked by Wall St. Rank hold IMVT as of Q3 2026.

  • Citigroup held 49,254 shares of Immunovant worth $1.66M as of Q3 2026.
  • Citigroup sold 66,891 Immunovant shares in Q3 2026, an estimated $2.64M.
  • Immunovant made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #2959 holding.
  • Citigroup first reported a position in Immunovant in Q1 2020 and has held it in 27 quarters since.
  • Citigroup's Immunovant position peaked at $8.07M in Q1 2024.
  • 50 funds tracked by Wall St. Rank held Immunovant as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.